The prevalence of depressive and anxiety symptoms in Polish epilepsy patients - The context of pharmaco-resistance

Epilepsy Behav. 2021 Jan;114(Pt A):107522. doi: 10.1016/j.yebeh.2020.107522. Epub 2020 Dec 1.

Abstract

Purpose: Patients with epilepsy (PWE) are at a higher risk of experiencing depressive and anxiety symptoms than the general population; these symptoms are more prevalent in patients with drug-resistant epilepsy (DRE) compared to those with non-drug-resistant epilepsy (NDRE). The aim of the present study was to compare the level of reported depressive and anxiety symptoms in patients with DRE and patients with NDRE and to examine the relationships between demographic and epilepsy-related variables and severity of depression and anxiety symptoms.

Material and methods: A total of 193 adult PWE, divided into a DRE group (n = 87), and an NDRE group (n = 106), completed the Beck Depression Inventory (BDI) and the Stat-Trait Anxiety Inventory (STAI-Sand STAI-T). Data analysis included sociodemographic and disease-related variables such as the type of epilepsy syndrome, age at onset of disease, and duration of the disease.

Results: The DRE group presented a higher score of BDI than the NDRE group (p = 0.04). Age correlated with the score of STAI-S in the NDRE group (r = 0.22). Sex was the only significant predictor of the score of STAI-T in the NDRE group. Men from the DRE group presented higher scores in BDI, STAI-S, and STA-T compared with the NDRE group.

Conclusions: Patients with DRE reported more severe depressive symptoms than patients with NDRE. In NDRE patients, the level of anxiety, considered as a state, was correlated with age. Sex was a significant predictor of the level of anxiety in DRE patients. Pharmaco-resistance was significantly associated with severity of depression and anxiety in male patients.

Keywords: Anxiety symptoms; Depressive symptoms; Drug-resistant epilepsy.

MeSH terms

  • Adult
  • Anxiety / epidemiology
  • Anxiety / etiology
  • Depression* / epidemiology
  • Depression* / etiology
  • Epilepsy* / complications
  • Epilepsy* / drug therapy
  • Epilepsy* / epidemiology
  • Humans
  • Male
  • Poland / epidemiology
  • Prevalence